Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.

Gandhi, Pranav K

Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. [electronic resource] - Journal of managed care & specialty pharmacy Feb 2015 - 165-75 p. digital

Publication Type: Comparative Study; Journal Article

2376-1032

10.18553/jmcp.2015.21.2.165 doi


Allopurinol--therapeutic use
Chronic Disease
Cost-Benefit Analysis
Febuxostat
Gout--blood
Gout Suppressants--therapeutic use
Humans
Markov Chains
Thiazoles--therapeutic use
Uric Acid--blood